期刊文献+

荧光原位杂交技术与传统核型分析在骨髓增生异常综合征异常克隆检测中的比较 被引量:2

A comparative study of fluorescence in situ hybridization versus conventional cytogenetics in thedetection of clonal aberrations in myelodysplastic syndrome
原文传递
导出
摘要 .7%(147/344),FISH对+8、20q-、-7/7q-、-5/5q-、-Y异常检出率分别为20.9%(72/344)、11.6%(40/344)、11.6%(40/344)、10.2%(35/344)、2.9%(6/206)。联合应用两种方法染色体异常率为54.4%(187/344)。8.9%(14/158)核型正常的患者FISH检测有异常克隆。9例CC为非克隆性异常的患者经FISH验证其中4例为克隆性异常。结论FISH能有效提高MDS常见染色体异常的检出率,并为部分CC正常或失败以及CC为非克隆性目的比较荧光原位杂交(FISH)和传统细胞遗传学(CC)对骨髓增生异常综合征(MDS)异常克隆检测的差异性,评价组合探针FISH在检测MDS常见染色体异常的价值。方法选取2008年6月至2012年10月北京大学人民医院诊治的344例初治的MDS患者,用CSF1R/D5S23-D5s721(5q33)、EGR1/D5S23-D5S721(5q31)、D7S486(7q31)/CSP7、D7s522(7q31)/CSP7、D20S108/CSP8(20q12/CSP8)和CSPX/CSPY共6组探针进行FISH检测,并与CC结果相比较。结果344例患者经cc检测染色体异常率为48.8%(168/344),主要异常为+8、20q-、-7/7q-、-5/5q-、-Y,异常检出率分别为18.9%(65/344)、9.3%(32/344)、8.4%(29/344)、8.4%(29/344)、2.4%(5/206);经FISH检测染色体异常率为42异常的MDS患者提供克隆性染色体异常的依据,是CC的有效补充。 Objective To compare the results of fluorescence in situ hybridization (FISH) versus conventional cytogenetics (CC) in the detection of common chromosomal abnormalities and evaluate the significance of FISH in myelodysplastic syndrome (MDS). Methods A total of 344 patients with de novo MDS from June 2008 to October 2012 were detected by 6 pairs of probes, including CSF1R/DSS23-DSS721 (5q33), EGR1/DSS23-DSS721(Sq31), DTS486(7q31)/CSPT, D7S522(7q31)/CSP7, D20S108/CSP8 (20q12/CSPS) and CSPX/CSPY. The results were compared with those of CC. Results CC revealed cytogenetic abnormalities in 168/344 cases (48.8%) and the frequency of common aberrations such as + 8, 20q , 7/7q -, -5/5q - and - Y were 18. 9% (65/344) ,9. 3% (32/344) ,8. 4% (29/344) ,8.4% (29/344) and 2.4% (5/206) respectively. While FISH revealed chromosome abnormalities in 147/344 patients (42.7%) and the frequency of +8, 20q-, -7/7q , 5/5q- and -Y were 20. 9% (72/344), 11.6% ( 40/344 ), 11.6% ( 40/344 ), 10. 2% ( 35/344 ) and 2. 9% ( 6/206 ) respectively.Overall 187/344 patients (54. 4% ) carried clonal aberrations by a combination of CC and FISH. Among 158 patients with normal karyotype by CC, 14 cases ( 8. 9% ) were detected to have clonal aberrations by FISH. FISH also confirmed 4 carriers of clonal aberrations out of 9 patients with nonclonal abnormalities by CC. Conclusions FISH is effective for improving the probability of detecting chromosome abnormalities in MDS cases with normal karyotypes and karyotype failure. FISH may provide rationales for clonal abnormalities in patients with nonclonal aberrations by CC. A combination of FISH and CC shows complementary advantages.
出处 《中华医学杂志》 CAS CSCD 北大核心 2013年第40期3175-3179,共5页 National Medical Journal of China
基金 中华医学会分子生物学临床应用研究专项基金(CAMB042010)
关键词 骨髓增生异常综合征 原位杂交 荧光 细胞遗传学 Myelodysplastic syndrome In situ hybridization,fluorescence Cytogenetics
  • 相关文献

参考文献17

  • 1Vanlet P, Horny HP, Bennet JM, et al. Definitions and standards in the diagnosis and treatment of the myelodysplastie snydromes: Consensus statements and report from a working conference. Leuk Res, 2007, 31: 727-736.
  • 2丘镜滢,党辉,任汉云,王德炳,段爱君.自体血浆培养体系对改善白血病骨髓细胞染色体的研究[J].北京医科大学学报,1993,25(4):249-251. 被引量:46
  • 3Shaffer LG, Tommerup NS. ISCN (2005) : An international system for human cytogenetic No2 menclature. Basel: Karger, 2005.
  • 4赖悦云,冯麟,王峥,吕珊,党辉,师岩,何琦,黄晓军.应用国产ES探针检测慢性髓系白血病的bcr/abl融合及der(9)中间缺失[J].中国实验血液学杂志,2010,18(1):199-203. 被引量:6
  • 5Olney HJ, Le Beau MM. The cytogenetics of myelodysplastic syndromes. Best Pract Res Clin Haematol,2001,14:479-495.
  • 6Haase D, Germing U, Schanz J, et al. New insights into prgnostic impact of the karyotype in MDS and correlation with subtypes: evidence from a core dataset of 2124 patients. Blood, 2007,110 : 4385-4395.
  • 7邱镜滢,赖悦云,柴晔,张艳,师岩,何琦,党辉,陆道培.306例骨髓增生异常综合征染色体核型的研究[J].中国实验血液学杂志,2004,12(4):455-459. 被引量:31
  • 8Chen L, Li J, Zhu Y, et al. Conventional and molecular cytogenetic features of myelodysplastic syndrome in China. Exp Onco1,2007,29 : 299-303.
  • 9Cherry AM, Brockman SR, Paternoster SF, et al. Comparison of interphase FISH and metaphase cytogenetics to study myelodysplastic syndrome: an Eastern Cooperative Oncology Group (ECOG) study. Leuk Res,2003,27 : 1085-1090.
  • 10Pitchford CW, Hettinga AC, Reichard KK, et al. Fluorescence in situ hybridization testing for - 5/5% - 7/7q, + 8, and del (20q) in primary myelodysplastic syndrome correlates with conventional cytogenetics in the setting of an adequate study. Am J Clin Pathol,2010,133:260-264.

二级参考文献43

  • 1薛永权.骨髓增生异常综合征的染色体分析[J].诊断学理论与实践,2005,4(5):354-356. 被引量:4
  • 2薛永权.伴有8;21染色体易位的骨髓增生异常综合征的新评价[J].国外医学(输血及血液学分册),1997,20(2):105-107. 被引量:1
  • 3ISCN (2005) : An International System for Human Cytogenetic Nomenclature. Shaffer LG, Tommerup NS. Karger, Basel.
  • 4Bennour A, Sennana H, Laatiri MA, et al. A masked BCR/ABL rearrangement in a case of chronic myeloid leukemia with translocation t(3;9) (p14;q34). Cancer Genet Cytogenet, 2008;181 (1) :72 - 74.
  • 5Todoric-Zivanovic B, Marisavljevic D, Surace C, et al. A Ph-negative chronic myeloid leukemia with a complex BCR/ABL rearrangement and a t(6 ;9 ) ( p21 ; q34.1 ). Cancer Genet Cytogenet, 2006 ; 166(2) :180 - 185.
  • 6Sessarego M, Fugazza G, Bruzzone R, et al. Complex chromosome rearangements may locate the bcr/abl fusion gene sites other than 22q11. Haematologica, 2000 ;85 ( 1 ) :35 - 39.
  • 7Storlazzi CT, Anelli L, Surace C, et al. Molecular cytogenetic characterization of a complex rearrangement involving chromosomes 9 and 22 in a case of Ph-negative chronic myeloid leukemia. Cancer Genet Cytogenet, 2002;136(2) :141 - 145.
  • 8Mark HF, Sokolic RA, Mark Y. Conventional cytogenetics and FISH in the detection of BCR/ABL fusion in chronic myeloid leukemia (CML). Exp Mol Pathol, 2006;81(1) :1 -7.
  • 9Lee DS, Lee YS, Yun YS, et al. A study on the incidence of ABL gene deletion on derivative chromosome 9 in chronic myelogenous leukemia by interphase fluorescence in situ hybridization and its asso- ciation with disease progression. Genes Chromosomes Cancer, 2003 ; 37(3) :291 -299.
  • 10Lee YK, Kim YR, Min HC, et al. Deletion of any part of the BCR or ABL gene on the derivative chromosome 9 is a poor prognostic marker in chronic myelogenous leukemia. Cancer Genet Cytogenet, 2006 ; 166 ( 1 ) :65 - 73.

共引文献86

同被引文献11

引证文献2

二级引证文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部